The potential risks of expedited approval of drugs for acute bacterial infections
- PMID: 25023994
- PMCID: PMC4232183
- DOI: 10.1001/jamainternmed.2014.3055
The potential risks of expedited approval of drugs for acute bacterial infections
Conflict of interest statement
Conflict of Interest Disclosure: Dr. Psaty reports serving on the data and safety monitoring board for a clinical trial of a cardiovascular device funded by the manufacturer (Zoll LifeCor VEST), which dose not relate to the topic of this article; on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson; and on the FDA Science Board.
References
- 
    - Food and Drug Administration. Guidance of Industry: Antibacterial Therapies for Patients with Unmet Medicine Need for the Treatment of Serious Bacterial Diseases. 2013 Jul; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
 
- 
    - Food and Drug Adminsitration. Gudiance for Industry: Expedited Programs for Serious Conditions - Drugs and Biologics. 2013 Jun; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
 
- 
    - Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996 Oct 1;125(7):605–613. - PubMed
 
- 
    - Food and Drug Adminsitration. Guidance for Industry. Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment. 2010 Nov; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
 
- 
    - Food and Drug Adminsitration. Meeting Materials, November 29, 2012 Meeting of the Anti-Infective Drugs Advisory Committee; http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/A....
 
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Medical
 
        